{
    "clinical_study": {
        "@rank": "58812", 
        "arm_group": [
            {
                "arm_group_label": "CC100 (3 single doses)", 
                "arm_group_type": "Experimental", 
                "description": "CC100 (3 single increasing doses by mouth).  Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose."
            }, 
            {
                "arm_group_label": "CC100 (2 single doses) & placebo(1 dose)", 
                "arm_group_type": "Experimental", 
                "description": "CC100 (2 single increasing doses by mouth) and placebo (1 single dose by mouth).  Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if CC100, given by mouth, is safe and is tolerated in\n      increasing doses.  How long the drug remains in the body will also be calculated."
        }, 
        "brief_title": "CC100: Safety and Tolerability of Single Doses", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Approximately 18 healthy subjects will be randomized to receive by mouth either 3 single\n      increasing doses of CC100 or 1 dose of placebo and 2 increasing doses of CC100.  Dosing will\n      occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.  Subjects\n      are required to stay in the Clinic for approximately 24 hours following each dose.  Subjects\n      may choose to have an optional lumbar puncture following the 3rd dose of study drug."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men must practice a reliable method of birth control during study and for 2 weeks\n             following study.  Women must be non-fertile or post-menopausal.\n\n        Exclusion Criteria:\n\n          -  Have serious or unstable illnesses as determined by the investigator.\n\n          -  Have current or a history of asthma, or severe drug allergies or pollen allergy.\n\n          -  Have used medications (except for calcium supplements or externally applied eye drops\n             or antibiotics) within 30 days prior to dosing or are expected to use other\n             medications during the study.\n\n          -  Have had serious infectious disease affecting the brain within the preceding 5 years;\n             or have known or existing evidence of serious infection.\n\n          -  Have laboratory test values that are considered clinically significant as determined\n             by the investigator.\n\n          -  Have ECG abnormalities that are clinically significant.\n\n          -  Have donated blood (a pint or more) or received an experimental drug within 30 days\n             prior to dosing.\n\n          -  Have a history of chronic alcohol or drug abuse within the past 2 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02050334", 
            "org_study_id": "CC100A"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CC100 (3 single doses)", 
                    "CC100 (2 single doses) & placebo(1 dose)"
                ], 
                "intervention_name": "CC100", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CC100 (2 single doses) & placebo(1 dose)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "Healthy Volunteer", 
            "Safety", 
            "Healthy Volunteer Safety Study"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "contact": {
                "email": "sguingri@iupui.edu", 
                "last_name": "Sandy Guingrich, LPN, CCRC", 
                "phone": "317-963-7382"
            }, 
            "facility": {
                "address": {
                    "city": "Indianapolis", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46202"
                }, 
                "name": "IU Health Neuroscience Center"
            }, 
            "investigator": {
                "last_name": "Robert M Pascuzzi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Protocol CC100A CC100: Safety and Tolerability of Single Doses", 
        "overall_contact": {
            "email": "sguingri@iupui.edu", 
            "last_name": "Sandy Guingrich, LPN, CCRC", 
            "phone": "317 963-7382"
        }, 
        "overall_official": {
            "affiliation": "IU Health Physicians - Neurology", 
            "last_name": "Robert M Pascuzzi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Vital signs, ECGs, adverse event reports, and laboratory test results will be analyzed according to dose.", 
            "measure": "Maximum tolerated dose", 
            "safety_issue": "Yes", 
            "time_frame": "Minimum of 24 hours after each dose."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02050334"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pharmacokinetic parameters, such as maximum concentration, time to peak concentration, apparent half life and clearance.", 
            "measure": "Pharmacokinetics (PK)", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "source": "Chemigen, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chemigen, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}